<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02168686</url>
  </required_header>
  <id_info>
    <org_study_id>ADVM-043-01</org_study_id>
    <nct_id>NCT02168686</nct_id>
  </id_info>
  <brief_title>Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency</brief_title>
  <acronym>ADVANCE</acronym>
  <official_title>Phase 1/2 Study of Intravenous or Intrapleural Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Alpha-1 Antitrypsin cDNA to Individuals With Alpha-1 Antitrypsin Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adverum Biotechnologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adverum Biotechnologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ADVANCE study is being conducted by Adverum Biotechnologies, Inc. as an open-label,
      multicenter, dose-escalation study in order to assess the safety and protein expression of
      ADVM-043 following a single intravenous or intrapleural administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alpha-1 Antitrypsin (A1AT) is a major inhibitor of serine proteases and plays an important
      role in the lung as an inhibitor of neutrophil elastase. A1AT deficiency is associated with
      decreases in plasma A1AT levels and is associated with an increased risk for developing
      asthma, emphysema/COPD, and bronchiectasis. Much of the lung damage is thought to be caused
      by proteolytic damage from neutrophil elastase and other proteases.

      ADVM-043 is an investigational gene therapy product (serotype AAVrh.10 vector) expressing
      human A1AT that is intended to deliver a functional gene to the liver of patients with A1AT
      deficiency. Study ADVM-043-01 will study up to 4 dose levels in up to 20 patients and assess
      the hypothesis that a single administration of an AAV vector expressing the human M-type A1AT
      (i.e., ADVM-043) to patients with A1AT deficiency is safe and results in persistent
      therapeutic levels of A1AT in blood and alveolar epithelial lining fluid (epithelial lining
      fluid is only to be collected in subjects who are dosed intrapleurally). The primary endpoint
      is safety, and changes in plasma A1AT levels at multiple time points up to 52 weeks after
      dosing. A prophylactic tapering corticosteroid regimen will be used to protect against
      potential vector induced transaminitis. Subjects will be followed for up to 52 weeks after
      dosing. Safety and efficacy data from the IV cohorts will be considered when determining
      whether to proceed to intrapleural administration. After completion of this study, subjects
      will be asked to enroll in a Long Term Follow Up study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Actual">August 29, 2019</completion_date>
  <primary_completion_date type="Actual">August 29, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Open-label, multicenter, dose-escalation clinical study to assess the safety and treatment effect of ADVM-043 in subjects with Alpha-1 Antitrypsin Deficiency.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and proportion of subjects experiencing adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Safety will be assessed by vital signs, ECG, blood work, immunological responses, pulmonary functions tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and proportion of subjects experiencing abnormal changes in clinical laboratory parameters</measure>
    <time_frame>1 year</time_frame>
    <description>Safety will be assessed by blood work and immunological responses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma concentrations of M-specific A1AT up to 52 weeks</measure>
    <time_frame>1 year</time_frame>
    <description>Efficacy will be assessed by measured bloodwork.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total plasma concentrations of A1AT up to 52 weeks</measure>
    <time_frame>1 year</time_frame>
    <description>Efficacy will be assessed by measured bloodwork.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Alpha 1-Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>Part A: Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADVM-043, at the lowest dose of three planned dose levels, of 8E13 total vg (equivalent to 1E12 vg/kg based on an 80-kg patient) administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADVM-043 at the intermediate dose of three planned dose levels, of 4E14 total vg (equivalent to 5E12 vg/kg based on an 80-kg patient) administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADVM-043 at the highest dose of three planned dose levels, of 1.2E15 total vg (equivalent to 1.5E13 vg/kg based on an 80-kg patient) administered IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADVM-043 administered at a dose that will be determined</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (optional): Intrapleural administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADVM-043 administered intrapleurally at a dose that will be determined</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ADVM-043</intervention_name>
    <description>Gene transfer vector administration</description>
    <arm_group_label>Part A: Dose 1</arm_group_label>
    <arm_group_label>Part A: Dose 2</arm_group_label>
    <arm_group_label>Part A: Dose 3</arm_group_label>
    <arm_group_label>Part A: Dose 4</arm_group_label>
    <arm_group_label>Part B (optional): Intrapleural administration</arm_group_label>
    <other_name>AAVrh.10halpha1AT</other_name>
    <other_name>AAVrh.10hA1AT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Capable of providing informed consent

          -  Alpha1AT genotype of ZZ or Z Null

          -  Males and females 18 years and older

          -  Ongoing treatment with A1AT augmentation is not required, however any subject
             receiving A1AT augmentation therapy must be willing to washout. Washout is defined as
             at least 8 weeks between last augmentation therapy and pre-treatment plasma A1AT level

          -  Willing to remain off PAT for at least 3 months following treatment

          -  Body mass index 18 to 35 kg/m2

          -  Fertile men and women of childbearing potential must agree to use barrier
             contraception for 3 months after treatment

        Key Exclusion Criteria:

          -  FEV1 &lt;35 percent of predicted value at the Screening visit

          -  Receiving systemic corticosteroids or other immunosuppressive medications

          -  Immunodeficiency disease or evidence of active infection of any type, including human
             immunodeficiency virus

          -  Abnormal liver function tests

          -  Organ transplant recipient or awaiting transplantation

          -  Participation in another current or previous gene transfer study

          -  AAVrh.10 neutralizing antibody titer â‰¥ 1:5

          -  Female who is pregnant or lactating

          -  History of alcohol or drug abuse within the past 5 years

          -  Any history of allergies that may prohibit study-specific investigations

          -  Receiving an investigational medicinal product or participating in another
             investigational study within 3 months prior to consent

          -  Cigarette smoking, or any other tobacco use, e-cigarettes or other recreational
             inhalant within 1 year of the Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlton Strange, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina, Charleston, SC, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Friedrich Kueppers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University Hospital, Philadelphia, PA, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Brantly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida, Gainesville, FL, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyle Hogarth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Medical Center, Chicago, IL, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor Barjakatarevic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ronald Reagan UCLA Medical Center, Santa Monica, CA, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2014</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alpha-1 antitrypsin deficiency</keyword>
  <keyword>alpha1-antitrypsin deficiency</keyword>
  <keyword>alpha-1-antitrypsin deficiency</keyword>
  <keyword>alpha1AT</keyword>
  <keyword>A1AT</keyword>
  <keyword>ADVM-043</keyword>
  <keyword>AAVrh.10halpha1AT</keyword>
  <keyword>AAVrh.10hA1AT</keyword>
  <keyword>Gene transfer vector</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>Lung disease</keyword>
  <keyword>Emphysema</keyword>
  <keyword>COPD</keyword>
  <keyword>ADVANCE study</keyword>
  <keyword>ADVM-043-01</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

